var data={"title":"Unoprostone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Unoprostone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7127?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=unoprostone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Unoprostone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160983\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rescula</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232423\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Docosanoid, Synthetic;</li>\n      <li>\n        Ophthalmic Agent, Antiglaucoma</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328381\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Open-angle glaucoma or ocular hypertension:</b> Ophthalmic: Instill 1 drop into affected eye(s) twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328382\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328383\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328384\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160984\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as isopropyl ester: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rescula: 0.15% (5 mL) [contains benzalkonium chloride, edetate disodium, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452749\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328385\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be used with other eye drops to lower intraocular pressure; if using more than one product, wait at least 5 minutes between application of each medication. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232401\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">To lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328365\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Ophthalmic: Burning sensation of eyes (&le;25%), stinging of eyes (&le;25%), eye pruritus (10% to 25%), eye redness (10% to 25%), xerophthalmia (10% to 25%), increased eyelash length (10% to 14%; &ge;1 mm at 12 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Foreign body sensation of eye (5% to 10%), dizziness, headache, insomnia, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Diabetes mellitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal lacrimation (5% to 10%), eyelid disease (5% to 10%), visual disturbance (5% to 10%), decreased eyelash length (7%), blepharitis, cataract, conjunctivitis, corneal lesion, eye discharge, eye irritation, eye pain, hemophthalmos, keratitis, photophobia, vitreous disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (6%), bronchitis, cough, pharyngitis, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Blepharoptosis, color blindness, corneal deposits, corneal edema, corneal opacity, diplopia, hyperpigmentation of eyelids, increased growth in number of eyelashes, increased intraocular pressure (acute), iris hyperpigmentation, iritis, optic atrophy, retinal hemorrhage, visual field defect</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328362\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to unoprostone or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328363\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular pigmentation: May cause permanent change in eye color (increases the amount of brown pigment in the iris, may not be noticeable for months to years); long-term consequences and potential injury to eye are not known. May also cause pigment changes to periorbital tissues and eyelashes during use; reversible upon discontinuation in most patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Bacterial keratitis, caused by inadvertent contamination of multiple-dose ophthalmic solutions, has been reported. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with intraocular inflammation (eg, uveitis); may exacerbate intraocular inflammatory conditions. May cause macular edema, including cystoid macular edema; use cautiously in aphakic patients, pseudophakic patients with torn posterior lens capsules, or in patients at risk for macular edema. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Contains benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contains benzalkonium chloride 0.015% as a preservative.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369113\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369111\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87470&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328359\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328360\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In animal reproduction studies, adverse events were observed when administered subcutaneously at doses greater than the recommended human dose. Following ophthalmic administration, systemic absorption is minimal; systemic absorption would be required in order for unoprostone to cross the placenta and reach the fetus. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples, 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328441\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if unoprostone is excreted in breast milk; however, systemic absorption is minimal following ophthalmic administration. The manufacturer recommends that caution be exercised when administering unoprostone to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328372\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The exact mechanism of action is unknown; however, unoprostone likely decreases IOP by increasing the outflow of aqueous humor. Cardiovascular and pulmonary function were not affected in clinical studies. IOP was decreased by 3-4 mm Hg in patients with a mean baseline IOP of 23 mm Hg. IOP may also be lowered by increased trabecular meshwork outflow via stimulation of calcium-activated BK and CIC-2 type channels (Fung, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16328374\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Through cornea and conjunctival epithelium (minimal systemic exposure)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed by esterases unoprostone-free acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 14 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570488\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rescula Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15% (5 mL): $153.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059479\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Rescula (BB, JP, KR, PH, PK, RU, TW, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Day DG, Schacknow PN, Wand M, et al, &ldquo;Timolol 0.5%/Dorzolamide 2% Fixed Combination vs Timolol Maleate 0.5% and Unoprostone 0.15% Given Twice Daily to Patients With Primary Open-Angle Glaucoma or Ocular Hypertension,&rdquo; <i>Am J Ophthalmol</i>, 2003, 135(2):138-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/unoprostone-drug-information/abstract-text/12566015/pubmed\" target=\"_blank\" id=\"12566015\">12566015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fung DS, Whitson JT. An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy. <i>Clin Ophthalmol</i>. 2014;8:543-554. doi: 10.2147/OPTH.S41562.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/unoprostone-drug-information/abstract-text/24648719/pubmed\" target=\"_blank\" id=\"24648719\">24648719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harms NV and Toris CB, &ldquo;Current Status of Unoprostone for the Management of Glaucoma and the Future of Its Use in the Treatment of Retinal Disease,&rdquo; <i>Expert Opin Pharmacother</i>, 2013, 14(1);105-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/unoprostone-drug-information/abstract-text/23199345/pubmed\" target=\"_blank\" id=\"23199345\">23199345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR and Meyer SM, &ldquo;Use of Ophthalmic Medications in Pregnant and Nursing Women,&rdquo; <i>Am J Ophthalmol</i>, 1988, 106(5):616-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/unoprostone-drug-information/abstract-text/2903673/pubmed\" target=\"_blank\" id=\"2903673\">2903673</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87470 Version 46.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16160983\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F232423\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16328381\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16328382\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16328383\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16328384\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16160984\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452749\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16328385\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F232401\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16328365\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16328362\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16328363\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369113\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369111\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16328359\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16328360\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16328441\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16328372\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16328374\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570488\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059479\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87470|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=unoprostone-patient-drug-information\" class=\"drug drug_patient\">Unoprostone: Patient drug information</a></li></ul></div></div>","javascript":null}